Wall Street Journal Interview with Bob Weinberg, Co-founder of Flagship Ventures company Theracrine, on his Work in Understanding Cancer

Wall Street Journal Interview with Bob Weinberg, Co-founder of Flagship Ventures company Theracrine, on his Work in Understanding Cancer

April 13, 2010

Bob Weinberg, co-founder of Flagship Ventures company Theracrine, was quoted in the Wall Street Journal about his leading work in understanding the biology of metastasis. Flagship Ventures founded Theracrine with Bob Weinberg, as well as Joan Massague, Doug Hanahan, and Michael Rosenblatt in 2008 to develop drugs to treat metastasis by interrupting Malignant Plasticity.

As highlighted in this story, Professor Weinberg, along with Theracrine's other co-founders, is leading an effort in understanding how Malignant Plasticity--the biology by which genetically altered cells co-opt normal signals from the body for maintenance, growth and development--affects tumor cell biology, and more importantly, how it can be interrupted, breaking the supply lines critical to cancer.